Branford, S., & Müller, M. C. (2012). Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib. Journal of clinical oncology, 30(35), . https://doi.org/10.1200/JCO.2011.40.5217
Chicago-Zitierstil (17. Ausg.)Branford, Susan, und Martin Christian Müller. "Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib." Journal of Clinical Oncology 30, no. 35 (2012). https://doi.org/10.1200/JCO.2011.40.5217.
MLA-Zitierstil (9. Ausg.)Branford, Susan, und Martin Christian Müller. "Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib." Journal of Clinical Oncology, vol. 30, no. 35, 2012, https://doi.org/10.1200/JCO.2011.40.5217.